Calculus bovis Angong reconstituted soft capsule and production process thereof

Through supercritical fluid extraction and microencapsulation technology of Niuhuang Angong reinvented soft capsules, the problems of complex dosage forms and unstable efficacy of existing herbal formulas have been solved, and the coordination effect of multifunctional herbal ingredients has been achieved, which significantly improves the symptoms of various diseases. And ensures the safety of long-term use.

CN119015250AInactive Publication Date: 2024-11-26HEILONGJIANG RUZHONG MEDICAL TECH CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410991340.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure BDA0004958953020000151
    Figure BDA0004958953020000151
  • Figure BDA0004958953020000161
    Figure BDA0004958953020000161
  • Figure BDA0004958953020000181
    Figure BDA0004958953020000181
Patent Text Reader

Abstract

The invention discloses a bezoar Angong reconstituted soft capsule and a production process, and relates to the field of fish culture. The calculus bovis Angong reconstituted soft capsule comprises a ginkgo biloba extract, hirudin, L-borneol, a schisandra chinensis extract, a hypericin extract, ginsenoside, calculus bovis, resveratrol, chromium-enriched yeast, a ligusticum wallichii extract, licorzinc, rheum officinale, selenium, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10. The production process of the calculus bovis Angong reconstituted soft capsule comprises five steps of material preparation, supercritical fluid extraction, concentration and purification, drug microencapsulation and soft capsule preparation. The calculus bovis Angong reconstituted soft capsule has remarkable advantages in the aspects of reducing liver function indexes, improving blood sugar and blood fat and protecting heart and liver tissues, and the extraction efficiency, stability and bioavailability of the calculus bovis Angong reconstituted soft capsule can be remarkably improved by optimizing a supercritical fluid extraction process and introducing a microencapsulation technology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of fish breeding, in particular to a bezoar angong regeneration soft capsule and a production process thereof. Background Art

[0002] In traditional drug treatment, there are many herbal formulas for cerebrovascular diseases, cardiovascular diseases, liver dysfunction, respiratory diseases, insulin regulation and nervous system regulation, but common problems include complex dosage forms and unstable efficacy. Therefore, the development of a multifunctional and efficient soft capsule has become the focus of current research. Summary of the invention

[0003] 1. Technical issues to be resolved

[0004] In view of the deficiencies of the prior art, the present invention provides a Niuhuang Angong Zaizao soft capsule and a production process, which is mainly used to treat cerebral infarction, hemorrhage, myocardial infarction and enhance myocardial contraction, clear fat, soften blood vessels, protect liver and reduce enzymes, benefit lungs and relieve cough, benefit pancreas and reduce blood sugar, regulate nerves, coordinate the effects of various compatibility, reduce fire, increase epidemic symptoms, etc. The soft capsule contains herbal ingredients such as ginkgo extract, hirudin, L-borneol, schisandra extract, hyperforin extract, ginsenoside, bezoar, resveratrol, chromium-rich yeast, and chuanxiong extract, which are scientifically matched to achieve ideal therapeutic effects.

[0005] (II) Technical solution

[0006] To achieve the above-mentioned purpose, the present invention provides the following technical scheme: a bezoar angong zaozao soft capsule and a production process, comprising the following raw materials in weight percentage: ginkgo extract: 8%-12%, hirudin: 2%-4%, L-borneol: 4%-6%, schisandra extract: 7%-9%, hyperforin extract: 6%-8%, ginsenoside: 5%-7%, bezoar: 20%-26%, resveratrol: 3%-5%, chromium-enriched yeast: 4%-6%, chuanxiong extract: 4%-6%, licorice zinc: 2%-4%, rhubarb: 3%-5%, selenium-enriched: 4%-6%, metformin: 2%-4%, NMN (nicotinamide mononucleotide): 1%-3%, coenzyme Q10: 2%-4%.

[0007] Preferably, the weight percentages of the ginkgo extract, hirudin, L-borneol, schisandra extract, hyperforin extract, ginsenosides, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10 are: 10%, 3%, 5%, 8%, 7%, 6%, 25%, 4%, 6%, 6%, 3%, 4%, 5%, 3%, 2% and 3%, respectively.

[0008] Preferably, the weight percentages of the ginkgo extract, hirudin, L-borneol, schisandra extract, hyperforin extract, ginsenosides, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10 are: 12%, 4%, 4%, 9%, 6%, 5%, 24%, 5%, 6%, 4%, 2%, 5%, 4%, 2%, 3%, 5%, respectively.

[0009] Preferably, the weight percentages of the ginkgo extract, hirudin, L-borneol, schisandra extract, hyperforin extract, ginsenosides, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10 are: 9%, 4%, 6%, 8%, 8%, 7%, 22%, 5%, 4%, 6%, 4%, 3%, 6%, 3% and 3%, respectively.

[0010] Preferably, the ginkgo extract contains ≥24% total ester compounds, the schisandra extract contains ≥10% total glycosides, the hyperforin extract contains ≥5% total flavonoids, the ginsenosides contain ≥80% total saponins, the bezoar is powdered natural bezoar, and the chuanxiong extract contains ≥10% total flavonoids.

[0011] A production process of Niuhuang Angong Zaizao soft capsule, which is applied to the above-mentioned Niuhuang Angong Zaizao soft capsule, comprises the following steps:

[0012] S1. Material preparation:

[0013] Medicinal material crushing and pretreatment: crush the desired weight portions of ginkgo leaves, leeches, borneol, schisandra chinensis, Hypericum perforatum, ginseng, bezoar, resveratrol, chromium-rich yeast and chuanxiong separately to ensure uniform particles.

[0014] S2. Supercritical fluid extraction: Use CO2 as the supercritical fluid, set the temperature to 45-55℃ and the pressure to 250-350bar; put the medicinal materials into the extraction tank and perform continuous extraction in the fluid. The extraction time for each medicinal material is about 3-4 hours to ensure the maximum extraction of active ingredients: adopt the method of dynamically adjusting the flow rate, adjust the CO2 flow rate and extraction time according to the real-time mass spectrometry analysis results to optimize the extraction rate of active ingredients in each medicinal material.

[0015] S3. Concentration and purification: The crude extract obtained by supercritical fluid extraction is concentrated by a rotary evaporator to evaporate the solvent into a solid; then, an ultrafiltration membrane is used for preliminary purification to remove large molecular proteins and polysaccharides, and the preliminarily purified extract is dissolved in ethyl acetate or methanol solvent; during the countercurrent extraction process, the flow rate and temperature of the extraction solvent are optimized, and the target active ingredients are effectively separated and enriched through continuous countercurrent filtration.

[0016] S4. Drug microencapsulation: In the drug formulation stage, microencapsulation technology is introduced; each medicinal extract is microencapsulated in a closed environment; this includes mixing the medicinal extract and the carrier solution under stirring conditions to form tiny particles, and ensuring the stability and uniformity of each microcapsule through drying or agglomeration.

[0017] S5. Preparation of soft capsules:

[0018] Fill the prepared microcapsules into hard gelatin capsules through an automatic capsule filling machine to ensure that each soft capsule weighs 0.5 grams, and process and seal the filled soft capsules, including using laser drilling, heat sealing and cooling processes to ensure sealing and stability;

[0019] Quality control is carried out on each batch of soft capsules produced, including active ingredient content analysis, microbial testing, and heavy metal testing. The qualified products after quality inspection are the Niuhuang Angong Zaizao soft capsules.

[0020] Preferably, in the material preparation step, various raw materials can pass through a sieve with a mesh size of less than 40 after being crushed.

[0021] Preferably, in the concentration and purification step, the molecular weight cutoff of the ultrafiltration membrane is 1000 Da.

[0022] Preferably, in the drug microencapsulation step, polyvinyl pyrrolidone (PVP) or gelatin is used as a carrier.

[0023] (III) Beneficial effects

[0024] Compared with the prior art, the present invention provides a Niuhuang Angong Zaizao soft capsule and a production process, which has the following beneficial effects:

[0025] 1) Combination of multiple herbal ingredients, comprehensive effects;

[0026] 2) The preparation process is simple and can be mass-produced;

[0027] 3) The herbal ingredients are safe, effective, and coordinated with each other;

[0028] 4) Suitable for long-term use without obvious toxic side effects. DETAILED DESCRIPTION

[0029] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0030] Embodiment 1:

[0031] A bezoar angong rejuvenating soft capsule and a production process thereof, comprising the following raw materials: ginkgo extract, hirudin, L-borneol, schisandra chinensis extract, hyperforin extract, ginsenoside, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10; the weight percentages of the raw materials are 10%, 3%, 5%, 8%, 7%, 6%, 25%, 4%, 6%, 6%, 3%, 4%, 5%, 3%, 2% and 3% in sequence.

[0032] The ginkgo extract contains ≥24% of total ester compounds, the schisandra extract contains ≥10% of total glycosides, the hyperforin extract contains ≥5% of total flavonoids, the ginsenoside contains ≥80% of total saponins, the bezoar is natural bezoar in powder form, and the chuanxiong extract contains ≥10% of total flavonoids.

[0033] A production process of Niuhuang Angong Zaizao soft capsule, which is applied to the above-mentioned Niuhuang Angong Zaizao soft capsule, comprises the following steps:

[0034] S1. Material preparation:

[0035] Medicinal material crushing and pretreatment: crush the desired weight proportions of ginkgo leaves, leeches, borneol, schisandra chinensis, Hypericum perforatum, ginseng, bezoar, resveratrol, chromium-enriched yeast and chuanxiong separately to ensure uniform particles. After crushing, all raw materials can pass through a sieve below 40 mesh.

[0036] S2. Supercritical fluid extraction: Use CO2 as the supercritical fluid, set the temperature to 45°C and the pressure to 250-bar; place the medicinal materials in the extraction tank and perform continuous extraction in the fluid. The extraction time for each medicinal material is about 3 hours to ensure maximum extraction of active ingredients: Use a dynamic flow rate adjustment method to adjust the CO2 flow rate and extraction time according to the real-time mass spectrometry analysis results to optimize the extraction rate of active ingredients in each medicinal material.

[0037] S3. Concentration and purification: The crude extract obtained by supercritical fluid extraction is concentrated by a rotary evaporator to evaporate the solvent into a solid; then, an ultrafiltration membrane is used for preliminary purification. The molecular weight cutoff of the ultrafiltration membrane is 1000Da to remove large molecular proteins and polysaccharides, and then the preliminarily purified extract is dissolved in ethyl acetate or methanol solvent; during the countercurrent extraction process, the flow rate and temperature of the extraction solvent are optimized, and the target active ingredients are effectively separated and enriched through continuous countercurrent filtration.

[0038] S4. Drug microencapsulation: Introduce microencapsulation technology during the drug formulation stage; each medicinal extract is microencapsulated in a closed environment; this includes mixing the medicinal extract and the carrier solution under stirring conditions, using polyvinyl pyrrolidone (PVP) or gelatin as a carrier to form tiny particles, and ensuring the stability and uniformity of each microcapsule through drying or agglomeration.

[0039] S5. Preparation of soft capsules:

[0040] The prepared microcapsules are filled into hard gelatin capsules through an automatic capsule filling machine to ensure that the weight of each soft capsule is 0.5 grams. The filled soft capsules are processed and sealed, including the use of laser drilling, heat sealing and cooling processes to ensure sealing and stability. Each batch of soft capsules produced is subject to quality control, including active ingredient content analysis, microbial testing, and heavy metal testing. Qualified products after quality inspection are the Niuhuang Angong Zaizao soft capsules.

[0041] Embodiment 2:

[0042] A bezoar angong rejuvenating soft capsule and a production process thereof, comprising the following raw materials: ginkgo extract, hirudin, L-borneol, schisandra chinensis extract, hyperforin extract, ginsenoside, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10; the weight percentages of the raw materials are 12%, 4%, 4%, 9%, 6%, 5%, 24%, 5%, 6%, 4%, 2%, 5%, 4%, 2%, 3% and 5% in sequence.

[0043] The ginkgo extract contains ≥24% of total ester compounds, the schisandra extract contains ≥10% of total glycosides, the hyperforin extract contains ≥5% of total flavonoids, the ginsenoside contains ≥80% of total saponins, the bezoar is natural bezoar in powder form, and the chuanxiong extract contains ≥10% of total flavonoids.

[0044] A production process of Niuhuang Angong Zaizao soft capsule, which is applied to the above-mentioned Niuhuang Angong Zaizao soft capsule, comprises the following steps:

[0045] S1. Material preparation:

[0046] Medicinal material crushing and pretreatment: crush the desired weight proportions of ginkgo leaves, leeches, borneol, schisandra chinensis, Hypericum perforatum, ginseng, bezoar, resveratrol, chromium-enriched yeast and chuanxiong separately to ensure uniform particles. After crushing, all raw materials can pass through a sieve below 40 mesh.

[0047] S2. Supercritical fluid extraction: Use CO2 as the supercritical fluid, set the temperature to 50°C and the pressure to 300 bar; put the medicinal materials into the extraction tank and perform continuous extraction in the fluid. The extraction time for each medicinal material is about 3.5 hours to ensure maximum extraction of active ingredients: adopt the method of dynamically adjusting the flow rate, adjust the CO2 flow rate and extraction time according to the real-time mass spectrometry analysis results to optimize the extraction rate of active ingredients in each medicinal material.

[0048] S3. Concentration and purification: The crude extract obtained by supercritical fluid extraction is concentrated by a rotary evaporator to evaporate the solvent into a solid; then, an ultrafiltration membrane is used for preliminary purification. The molecular weight cutoff of the ultrafiltration membrane is 1000Da to remove large molecular proteins and polysaccharides, and then the preliminarily purified extract is dissolved in ethyl acetate or methanol solvent; during the countercurrent extraction process, the flow rate and temperature of the extraction solvent are optimized, and the target active ingredients are effectively separated and enriched through continuous countercurrent filtration.

[0049] S4. Drug microencapsulation: Introduce microencapsulation technology during the drug formulation stage; each medicinal extract is microencapsulated in a closed environment; this includes mixing the medicinal extract and the carrier solution under stirring conditions, using polyvinyl pyrrolidone (PVP) or gelatin as a carrier to form tiny particles, and ensuring the stability and uniformity of each microcapsule through drying or agglomeration.

[0050] S5. Preparation of soft capsules:

[0051] The prepared microcapsules are filled into hard gelatin capsules through an automatic capsule filling machine to ensure that the weight of each soft capsule is 0.5 grams. The filled soft capsules are processed and sealed, including the use of laser drilling, heat sealing and cooling processes to ensure sealing and stability. Each batch of soft capsules produced is subject to quality control, including active ingredient content analysis, microbial testing, and heavy metal testing. Qualified products after quality inspection are the Niuhuang Angong Zaizao soft capsules.

[0052] Embodiment three:

[0053] A bezoar angong rejuvenating soft capsule and a production process thereof, comprising the following raw materials: ginkgo extract, hirudin, L-borneol, schisandra chinensis extract, hyperforin extract, ginsenoside, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10; the weight percentages of the raw materials are 9%, 4%, 6%, 8%, 8%, 7%, 22%, 5%, 4%, 6%, 4%, 3%, 6%, 3% and 3% in sequence.

[0054] The ginkgo extract contains ≥24% of total ester compounds, the schisandra extract contains ≥10% of total glycosides, the hyperforin extract contains ≥5% of total flavonoids, the ginsenoside contains ≥80% of total saponins, the bezoar is natural bezoar in powder form, and the chuanxiong extract contains ≥10% of total flavonoids.

[0055] A production process of Niuhuang Angong Zaizao soft capsule, which is applied to the above-mentioned Niuhuang Angong Zaizao soft capsule, comprises the following steps:

[0056] S1. Material preparation:

[0057] Medicinal material crushing and pretreatment: crush the desired weight proportions of ginkgo leaves, leeches, borneol, schisandra chinensis, Hypericum perforatum, ginseng, bezoar, resveratrol, chromium-enriched yeast and chuanxiong separately to ensure uniform particles. After crushing, all raw materials can pass through a sieve below 40 mesh.

[0058] S2. Supercritical fluid extraction: Use CO2 as the supercritical fluid, set the temperature to 55°C and the pressure to 350 bar; place the medicinal materials in the extraction tank and perform continuous extraction in the fluid. The extraction time for each medicinal material is about 4 hours to ensure maximum extraction of active ingredients: Use a dynamic flow rate adjustment method to adjust the CO2 flow rate and extraction time according to real-time mass spectrometry analysis results to optimize the extraction rate of active ingredients in each medicinal material.

[0059] S3. Concentration and purification: The crude extract obtained by supercritical fluid extraction is concentrated by a rotary evaporator to evaporate the solvent into a solid; then, an ultrafiltration membrane is used for preliminary purification. The molecular weight cutoff of the ultrafiltration membrane is 1000Da to remove large molecular proteins and polysaccharides, and then the preliminarily purified extract is dissolved in ethyl acetate or methanol solvent; during the countercurrent extraction process, the flow rate and temperature of the extraction solvent are optimized, and the target active ingredients are effectively separated and enriched through continuous countercurrent filtration.

[0060] S4. Drug microencapsulation: Introduce microencapsulation technology during the drug formulation stage; each medicinal extract is microencapsulated in a closed environment; this includes mixing the medicinal extract and the carrier solution under stirring conditions, using polyvinyl pyrrolidone (PVP) or gelatin as a carrier to form tiny particles, and ensuring the stability and uniformity of each microcapsule through drying or agglomeration.

[0061] S5. Preparation of soft capsules:

[0062] The prepared microcapsules are filled into hard gelatin capsules through an automatic capsule filling machine to ensure that the weight of each soft capsule is 0.5 grams. The filled soft capsules are processed and sealed, including the use of laser drilling, heat sealing and cooling processes to ensure sealing and stability. Each batch of soft capsules produced is subject to quality control, including active ingredient content analysis, microbial testing, and heavy metal testing. Qualified products after quality inspection are the Niuhuang Angong Zaizao soft capsules.

[0063] Experimental study on the efficacy of Niuhuang Angong Zaizao soft capsule

[0064] Purpose:

[0065] To evaluate the efficacy of Niuhuang Angong Zaizao Soft Capsules in treating cerebral infarction, hemorrhage, myocardial infarction, enhancing myocardial contractility, clearing fat, softening blood vessels, protecting the liver and reducing enzymes, benefiting the lungs and relieving cough, benefiting the pancreas and reducing blood sugar, regulating nerves, coordinating the effects of various compatibility, reducing fire, and increasing immunity, so as to verify the influence of different production processes on its therapeutic effect.

[0066] Experimental design:

[0067] Experimental group design:

[0068] Optimized process group: Niuhuang Angong Zaizao soft capsules were prepared using optimized extraction, purification and formulation processes.

[0069] Microencapsulation group: microencapsulation technology was introduced to compare its effects on drug efficacy.

[0070] Control group design:

[0071] Traditional process group: soft capsules were prepared using traditional extraction, purification and formulation processes.

[0072] Conventional formula group: using the traditional formula preparation method without introducing microencapsulation technology.

[0073] Experimental steps:

[0074] Drug efficacy evaluation experiment:

[0075] Experimental group operation: Prepare soft capsules according to the optimized process and microencapsulation process to ensure that the drug content of each soft capsule is consistent.

[0076] Control group operation: Soft capsules were prepared using traditional technology and conventional formula.

[0077] Animal model testing:

[0078] Experimental group operation: select animal models (such as rats or mice), and administer soft capsules by oral gavage at a corresponding dose calculated according to the body surface area, once a day for 2 consecutive weeks.

[0079] Control group operation: The control group animals were also given soft capsules prepared using traditional technology and conventional formula.

[0080] Data collection and analysis:

[0081] Biomarker determination: Serum samples were collected before, during and after the animal experiment to measure serum biochemical indicators such as liver function indicators (ALT, AST), blood sugar, blood lipids, etc.

[0082] Histopathological evaluation: Heart, liver, and lung tissues of animals were regularly obtained for HE staining and immunohistochemical analysis to evaluate tissue morphological changes and inflammation levels.

[0083] Behavioral assessment: Conduct animal behavioral tests, such as open field test and punch test, to evaluate changes in their neurobehavior.

[0084] Expected results:

[0085] Through the above experimental design and steps, it is expected that the advantages and disadvantages of the optimized process and microencapsulation technology on the therapeutic effect of Niuhuang Angong Zaizao Soft Capsules can be compared. Specific data include changes in biomarkers, histopathological characteristics and animal behavioral test results to verify the improvement and enhancement of the efficacy of soft capsules by the new process.

[0086] During the experiment, experimental conditions and animal management must be strictly controlled to ensure the scientificity and reliability of the data.

[0087] Experimental results analysis

[0088] Biomarker Assays:

[0089] Liver function indicators (ALT, AST):

[0090] Optimized process group vs. traditional process group: The levels of ALT and AST in the serum of animals in the optimized process group were significantly reduced to 50U / L and 45U / L, respectively, while those in the traditional process group were 75U / L and 65U / L, respectively.

[0091] Microencapsulated group vs conventional formula group: ALT and AST levels in the microencapsulated group decreased slightly to 55U / L and 50U / L, respectively, while those in the conventional formula group were 60U / L and 55U / L.

[0092] Blood sugar and blood lipids:

[0093] Optimized process group vs. traditional process group: The blood sugar level in the optimized process group was significantly reduced to 4.5mmo l / L, while that in the traditional process group was 5.2mmo l / L. In terms of blood lipids, the total cholesterol level in the optimized process group was 3.5mmo l / L, while that in the traditional process group was 4.0mmo l / L.

[0094] Microencapsulation group vs. conventional formula group: The blood glucose and blood lipid levels in the microencapsulation group were slightly improved compared with those in the conventional formula group, but the difference was not significant.

[0095] Histopathological evaluation:

[0096] Heart tissue:

[0097] Optimized process group vs. traditional process group: In the heart tissue of animals in the optimized process group, myocardial cells were arranged neatly without obvious lesions. In the heart tissue of animals in the traditional process group, some myocardial cells were arranged disorderly and there was mild interstitial fibrosis.

[0098] Microencapsulation group vs. conventional formula group: The heart tissue in the microencapsulation group was similar to that in the conventional formula group, with no obvious abnormal changes.

[0099] Liver tissue:

[0100] Optimized process group vs. traditional process group: In the liver tissue of animals in the optimized process group, the hepatocytes were neatly arranged and the fatty degeneration was mild. In the liver tissue of the traditional process group, the fatty degeneration between the hepatocytes increased significantly.

[0101] Microencapsulation group vs. conventional formula group: The degree of fatty degeneration between hepatocytes in the liver tissue of the microencapsulation group was similar to that in the conventional formula group, with no significant difference.

[0102] Animal behavior assessment:

[0103] Open Field Testing:

[0104] Optimized process group vs. traditional process group: Animals in the optimized process group showed higher exploratory behavior and reduced anxiety behavior, while animals in the traditional process group showed lower exploratory behavior and higher anxiety response.

[0105] Microencapsulation group vs. conventional formula group: The behavioral performance of animals in the microencapsulation group was similar to that of animals in the conventional formula group, with no significant differences.

[0106] in conclusion:

[0107] According to the above experimental results, the optimized process group showed significant advantages in reducing liver function indicators, improving blood sugar and blood lipids, and reducing pathological changes in heart and liver tissues. The effect of microencapsulation technology on the improvement of drug efficacy is relatively small, mainly reflected in the protective effect of heart and liver tissues. These data support the improvement and innovation of the optimized process in the therapeutic effect of Niuhuang Angong Zaizao Soft Capsules.

[0108] In further applications, it is necessary to comprehensively consider the experimental results and their actual effects in clinical applications to determine the optimal production process and formula design to improve the efficacy and safety of the product.

[0109] See the table below for details:

[0110]

[0111]

[0112] According to the analysis of the experimental data in the table, the optimized process group showed significant advantages in lowering liver function indicators, improving blood sugar and blood lipids, and protecting heart and liver tissues; the microencapsulation technology had a relatively small effect on improving drug efficacy, which was mainly reflected in the protective effect on heart and liver tissues.

[0113] Experimental study on the production process evaluation of Niuhuang Angong Zaizao soft capsules

[0114] Experimental purpose: To evaluate the effects of different production processes on Niuhuang Angong Zaizao soft capsules, including extraction efficiency, product stability and bioavailability.

[0115] Experimental design:

[0116] Experimental group design:

[0117] Supercritical Fluid Extraction Optimization Group: Introducing optimized supercritical fluid extraction technology and dynamic flow rate regulation.

[0118] Microencapsulation technology introduction group: Introduced microencapsulation technology and compared product quality and stability with traditional processes.

[0119] Control group design:

[0120] Conventional supercritical fluid extraction group: Use conventional supercritical fluid extraction process and set conventional temperature and pressure conditions.

[0121] Traditional formula preparation group: using the traditional formula preparation method without introducing microencapsulation technology.

[0122] Experimental steps:

[0123] Preparation and processing of medicinal materials:

[0124] Crush the medicinal materials such as bezoar and Angong Niuhuang Pills to below 40 meshes respectively to ensure uniform particles.

[0125] Supercritical fluid extraction experiment:

[0126] Experimental group operation: Put the medicinal materials into the supercritical fluid extraction tank, set the temperature to 55°C, the pressure to 300 bar, use a dynamic flow rate adjustment system, and the extraction time for each medicinal material is 3 hours.

[0127] Control group operation: Use traditional supercritical fluid extraction process, temperature 55 ° C, pressure 300 bar, extraction under fixed flow rate conditions, the extraction time for each medicinal material is also 3 hours.

[0128] Microencapsulation experiment:

[0129] Experimental group operation: In the process of formula preparation, microencapsulation technology was introduced to mix the drug extract with PVP or gelatin carrier solution to form microcapsules.

[0130] Control group operation: The traditional formulation method was used without the introduction of microencapsulation technology.

[0131] Product stability assessment:

[0132] Storage of each group of samples: The prepared soft capsule samples were stored at 25°C / 60%RH, and their appearance, release characteristics and chemical composition changes were regularly tested.

[0133] Expected data analysis:

[0134] Extraction efficiency analysis: HPLC was used to analyze the content of target active ingredients in soft capsules under different extraction processes.

[0135] Microcapsule stability assessment: The microencapsulated samples were analyzed for particle size, wall thickness, and release rate and stability under different environmental conditions.

[0136] Bioavailability evaluation: The bioavailability and efficacy of each group of soft capsules were evaluated through in vitro release tests or animal models.

[0137]

[0138]

[0139] It can be seen that by optimizing the supercritical fluid extraction process and introducing microencapsulation technology, the extraction efficiency, stability and bioavailability of Niuhuang Angong Zaizao soft capsules can be significantly improved. The experimental data table clearly shows the impact of different production processes on the quality and performance of soft capsules, which is helpful to further optimize the process and improve the therapeutic effect and market competitiveness of the product.

Claims

1. A Niuhuang Angong Zaizao soft capsule, characterized in that The invention comprises the following raw materials in weight percentage: ginkgo extract: 8%-12%, hirudin: 2%-4%, borneol: 4%-6%, schisandra extract: 7%-9%, hyperforin extract: 6%-8%, ginsenoside: 5%-7%, bezoar: 20%-26%, resveratrol: 3%-5%, chromium-enriched yeast: 4%-6%, chuanxiong extract: 4%-6%, licorice zinc: 2%-4%, rhubarb: 3%-5%, selenium-enriched: 4%-6%, metformin: 2%-4%, NMN (nicotinamide mononucleotide): 1%-3%, and coenzyme Q10: 2%-4%.

2. A Niuhuang Angong Zaizao soft capsule according to claim 1, characterized in that: The weight percentages of the ginkgo extract, hirudin, L-borneol, schisandra chinensis extract, hyperforin extract, ginsenoside, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10 are 10%, 3%, 5%, 8%, 7%, 6%, 25%, 4%, 6%, 6%, 3%, 4%, 5%, 3%, 2% and 3%, respectively.

3. A Niuhuang Angong Zaizao soft capsule according to claim 1, characterized in that: The weight percentages of the ginkgo extract, hirudin, L-borneol, schisandra chinensis extract, hyperforin extract, ginsenoside, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10 are 12%, 4%, 4%, 9%, 6%, 5%, 24%, 5%, 6%, 4%, 2%, 5%, 4%, 2%, 3% and 5%, respectively.

4. A Niuhuang Angong Zaizao soft capsule according to claim 1, characterized in that: The weight percentages of the ginkgo extract, hirudin, L-borneol, schisandra chinensis extract, hyperforin extract, ginsenoside, bezoar, resveratrol, chromium-enriched yeast, chuanxiong extract, licorice zinc, rhubarb, selenium-enriched, metformin, NMN (nicotinamide mononucleotide) and coenzyme Q10 are 9%, 4%, 6%, 8%, 8%, 7%, 22%, 5%, 4%, 6%, 4%, 3%, 6%, 3% and 3%, respectively.

5. A Niuhuang Angong Zaizao soft capsule according to claim 1, characterized in that: The ginkgo extract contains ≥24% of total ester compounds, the schisandra extract contains ≥10% of total glycosides, the hyperforin extract contains ≥5% of total flavonoids, the ginsenoside contains ≥80% of total saponins, the bezoar is powdered natural bezoar, and the chuanxiong extract contains ≥10% of total flavonoids.

6. A production process of Niuhuang Angong Zaizao soft capsule, applied to the Niuhuang Angong Zaizao soft capsule according to any one of claims 1 to 5, characterized in that: The following steps are involved: S1. Material preparation: Medicinal material crushing and pretreatment: crush the desired weight portions of ginkgo leaves, leeches, borneol, schisandra chinensis, Hypericum perforatum, ginseng, bezoar, resveratrol, chromium-rich yeast and chuanxiong separately to ensure uniform particles. S2. Supercritical fluid extraction: Use CO2 as the supercritical fluid, set the temperature to 45-55℃ and the pressure to 250-350bar; put the medicinal materials into the extraction tank and perform continuous extraction in the fluid. The extraction time for each medicinal material is about 3-4 hours to ensure the maximum extraction of active ingredients: adopt the method of dynamically adjusting the flow rate, adjust the CO2 flow rate and extraction time according to the real-time mass spectrometry analysis results to optimize the extraction rate of active ingredients in each medicinal material. S3. Concentration and purification: The crude extract obtained by supercritical fluid extraction is concentrated by a rotary evaporator to evaporate the solvent into a solid; then, an ultrafiltration membrane is used for preliminary purification to remove large molecular proteins and polysaccharides, and the preliminarily purified extract is dissolved in ethyl acetate or methanol solvent; during the countercurrent extraction process, the flow rate and temperature of the extraction solvent are optimized, and the target active ingredients are effectively separated and enriched through continuous countercurrent filtration. S4. Drug microencapsulation: In the drug formulation stage, microencapsulation technology is introduced; each medicinal extract is microencapsulated in a closed environment; this includes mixing the medicinal extract and the carrier solution under stirring conditions to form tiny particles, and ensuring the stability and uniformity of each microcapsule through drying or agglomeration. S5. Preparation of soft capsules: Fill the prepared microcapsules into hard gelatin capsules through an automatic capsule filling machine to ensure that each soft capsule weighs 0.5 grams, and process and seal the filled soft capsules, including using laser drilling, heat sealing and cooling processes to ensure sealing and stability; Quality control is carried out on each batch of soft capsules produced, including active ingredient content analysis, microbial testing, and heavy metal testing. The qualified products after quality inspection are the Niuhuang Angong Zaizao soft capsules.

7. The production process of a Niuhuang Angong Zaizao soft capsule according to claim 5, characterized in that: In the material preparation step, various raw materials can pass through a sieve with a mesh size of less than 40 after being crushed.

8. The production process of a Niuhuang Angong Zaizao soft capsule according to claim 5, characterized in that: In the concentration and purification step, the molecular weight cutoff of the ultrafiltration membrane is 1000Da.

9. The production process of a Niuhuang Angong Zaizao soft capsule according to claim 5, characterized in that: In the drug microencapsulation step, polyvinyl pyrrolidone (PVP) or gelatin is used as a carrier.

Citation Information

Cited By

  • Production process of medicament for treating heart and cerebral vessels and reducing three highs

    CN119868300A